INS and Hypoglycemia: These systems aim to compensate for delays in infusion and action to mimic the first stage of physiological insulin secretion [36]. However, this strategy increases hypoglycaemia risk and, as such, requires a safety feedback controller to replicate β-cell suppression [37].